NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Duan, Zhenfeng ^a   Choy, Edwin ^a   Hornicek, Francis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CALCEIN; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NSC 23925; PACLITAXEL; PM 00104; RHODAMINE 123; TRABECTEDIN; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE; (2 (4 METHOXYPHENYL) 4 QUINOLINYL)(2 PIPERIDINYL)METHANOL; (2-(4-METHOXYPHENYL)-4-QUINOLINYL)(2-PIPERIDINYL)METHANOL; ADENOSINE TRIPHOSPHATASE; CALCEIN AM; FLUORESCEIN DERIVATIVE; GLYCOPROTEIN P; PIPERIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SENSITIZATION; DRUG STRUCTURE; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY CANCER; PROTEIN EXPRESSION; SARCOMA CELL; CHEMICAL MODEL; CHEMISTRY; DRUG RESISTANCE; FEMALE; METABOLISM; METHODOLOGY; OVARY TUMOR;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUORESCEINS; HUMANS; MODELS, CHEMICAL; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PIPERIDINES; QUINOLINES;

EID: 70350776281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007415     Document Type: Article

References (45)

1. Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9: 167-181.
2. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
3. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
4. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1-19.
5. Mellor HR, Callaghan R (2008) Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81: 275-300.
6. Mimeault M, Batra SK (2006) Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27: 1-22.
7. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV (2005) Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 55: 277-285.
8. Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, et al. (2009) Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 63: 1121-1129.
9. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV (2003) Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 63: 2200-2205.
10. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
11. Kaye SB (2008) Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol 26: 2616-2618.
12. Sikic BI (1997) Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 34: 40-47.
13. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, et al. (2000) Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 11: 1471-1476.
14. Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, et al. (1993) Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 67: 1031-1035.
15. Ferry DR, Traunecker H, Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070-1081.
16. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV (1999) TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229: 75-81.
17. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265-283.
18. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, et al. (2004) Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22: 4290-4301.
19. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, et al. (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 115: 895-902.
20. Twentyman PR, Bleehen NM (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer 27: 1639-1642.
21. te Boekhorst PA, van Kapel J, Schoester M, Sonneveld P (1992) Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmacol 30: 238-242.
22. Caldwell JS (2007) Cancer cell-based genomic and small molecule screens. Adv Cancer Res 96: 145-173.
23. Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, et al. (2007) 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol 72: 1137-1145.
24. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, et al. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6: 129-137.
25. Lourda M, Trougakos IP, Gonos ES (2007) Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Int J Cancer 120: 611-622.
26. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942.
27. Ulukaya E, Colakogullari M, Wood EJ (2004) Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy 50: 43-50.
28. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, et al. (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171-4179.
29. Dai CL, Xiong HY, Tang LF, Zhang X, Liang YJ, et al. (2007) Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother Pharmacol 60: 741-750.
30. Iorns E, Lord CJ, Ashworth A (2009) Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J 417: 361-370.
31. Zhu X, Sui M, Fan W (2005) In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res 25: 1953-1962.
32. Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, et al. (2005) Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65: 4852-4860.
33. Garrigues A, Nugier J, Orlowski S, Ezan E (2002) A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem 305: 106-114.
34. Litman T, Skovsgaard T, Stein WD (2003) Pumping of drugs by P-glycoprotein: a two-step process? J Pharmacol Exp Ther 307: 846-853.
35. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
36. Wang EJ, Casciano CN, Clement RP, Johnson WW (2000) In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 28: 522-528.
37. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46: 1716-1725.
38. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, et al. (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 20: 5615-5625.
39. Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446: 749-757.
40. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, et al. (1992) Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A 89: 8472-8476.
41. Hamada H, Tsuruo T (1988) Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res 48: 4926-4932.
42. Choi CH, Kim JH, Kim SH (2004) Reversal of P-glycoprotein-mediated MDR by 5,7,3′,4′,5′-pentamethoxyflavone and SAR. Biochem Biophys Res Commun 320: 672-679.
43. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, et al. (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49: 337-343.
44. Scarborough GA (2003) Rethinking the P-type ATPase problem. Trends Biochem Sci 28: 581-584.
45. Scarborough GA (2002) Molecular mechanism of the P-type ATPases. J Bioenerg Biomembr 34: 235-250.